サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428282

中枢神経系（CNS）バイオマーカーの世界市場レポート 2024

Central Nervous System Biomarkers Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
中枢神経系（CNS）バイオマーカーの世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

中枢神経系（CNS）バイオマーカーの市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.7%の年間平均成長率（CAGR）で80億2,000万米ドルに成長すると予想されます。予測期間中に予想される拡大は、神経疾患の有病率の上昇、個別化医療に対する需要の増大、高齢者人口の増加、早期診断の重視の高まり、非侵襲的診断ツールに対する需要の高まりによるものと考えられます。予測期間中に予想される注目すべき動向には、新たな技術の進歩、バイオテクノロジー企業、製薬会社、その他の利害関係者間の戦略的協力、脳脊髄液（CSF）と血液ベースのバイオマーカーに焦点を当てた研究の急増、AIと機械学習アルゴリズムの利用が含まれます。

神経疾患の予想される増加により、将来、中枢神経系（CNS）バイオマーカー市場の拡大が促進されると予想されます。神経疾患は神経疾患とも呼ばれ、脳、脊髄、全身の神経に影響を与える広範囲の症状を含みます。これらの障害は、遺伝的影響、感染症、自己免疫反応、変性過程、腫瘍、血管の問題、外傷などのさまざまな要因によって生じる可能性があります。神経疾患の領域では、中枢神経系（CNS）バイオマーカーは、臨床診断、病気のリスクや予後の判断、病気の段階の評価、治療反応のモニタリングにおいて重要な役割を果たします。これらは、これらの疾患とその治療可能性の理解に大きく貢献します。たとえば、2023年 4月、米国政府機関である疾病管理予防センターは、65歳以上の推定670万人の米国人がアルツハイマー病に罹患しており、この数は2060年までに3倍の1,400万人になるとの予測を報告しました。そのため、神経疾患の急増は中枢神経系（CNS）バイオマーカー市場の成長を推進する重要な要因となっています。

予測される肥満有病率の増加は、中枢神経系（CNS）バイオマーカー市場の成長を促進する態勢が整っています。健康に悪影響を及ぼす可能性のある過剰な体脂肪を特徴とする病状である肥満は、体重、摂食行動、および効果的な抗肥満治療法の開発を制御する神経学的メカニズムを理解するために、中枢神経系（CNS）バイオマーカーを使用して研究されます。たとえば、英国に本拠を置く政府機関である政府デジタルサービスは、2023年 5月の時点で、英国の個人（18歳以上）の25.9%が2021年から2022年に肥満になると予想されており、これは25.2%の増加に相当します。したがって、肥満の有病率のエスカレートは、中枢神経系（CNS）バイオマーカー市場の成長の重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 市場促進要因・市場抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 市場規模と成長実績、2018～2023年
  • 市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の中枢神経系（CNS）バイオマーカー市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 安全性バイオマーカー
  • 有効性バイオマーカー
  • 検証バイオマーカー
  • その他
  • 世界の中枢神経系（CNS）バイオマーカー市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 多発性硬化症
  • アルツハイマー病
  • パーキンソン病
  • 外傷性脳損傷
  • その他
  • 世界の中枢神経系（CNS）バイオマーカー市場、用途別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 創薬・医薬品開発
  • 個別化医療
  • 疾患リスク評価
  • 診断
  • その他
  • 世界の中枢神経系（CNS）バイオマーカー市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 診断研究所
  • クリニック
  • 病院
  • 研究センター
  • その他

第7章 地域および国の分析

  • 世界の中枢神経系（CNS）バイオマーカー市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の中枢神経系（CNS）バイオマーカー市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 中枢神経系（CNS）バイオマーカー市場の競合情勢
  • 中枢神経系（CNS）バイオマーカー市場の企業プロファイル
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc
    • Abbott Laboratories

第31章 その他の大手および革新的な企業

  • Merck KGaA
  • Eurofins Scientific
  • Charles River Laboratories International Inc.
  • PerkinElmer Inc.
  • Bio-Rad Laboratories Inc.
  • QIAGEN NV
  • Axon Neuroscience SE
  • Alector Inc.
  • Oryzon Genomics SA
  • Abastar Mdx Inc.
  • Banyan Biomarkers Inc.
  • Avacta Group PLC
  • Geno Technology Inc.
  • Anavex Life Sciences Corp.
  • Alseres Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14126

Central nervous system (CNS) biomarkers are specific substances or measurable indicators within the CNS that offer insights into normal functioning, disease processes, or responses to treatments. They play a crucial role in diagnosing or predicting neurological disorders, monitoring disease progression, and anticipating responses to drug therapy.

The primary categories of CNS biomarkers include safety biomarkers, efficacy biomarkers, validation biomarkers, and others. Safety biomarkers encompass measurable biological parameters or indicators employed to evaluate the safety of drugs, medical interventions, or environmental exposures. They find application in treating various diseases such as multiple sclerosis, Alzheimer's disease, traumatic brain injury, and more, contributing to drug discovery and development, personalized medicines, disease risk assessment, diagnostics, among other areas. Diverse end-users, such as diagnostic labs, clinics, hospitals, research centers, and others, utilize these biomarkers.

The central nervous system biomarkers market research report is one of a series of new reports from The Business Research Company that provides central nervous system biomarkers market statistics, including central nervous system biomarkers industry global market size, regional shares, competitors with a central nervous system biomarkers market share, detailed central nervous system biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system biomarkers industry. This central nervous system biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system biomarkers market size has grown rapidly in recent years. It will grow from $5.01 billion in 2023 to $5.55 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The increase in the historical period can be attributed to an escalation in concerns related to neurological disorders, a high prevalence of central nervous system illnesses, a growing demand for improved diagnosis and treatment, enhanced healthcare infrastructure, and an increase in the aging population.

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $8.02 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The expansion anticipated in the forecast period can be ascribed to the rising prevalence of neurological disorders, an increasing demand for personalized medicine, a growing geriatric population, a heightened emphasis on early diagnosis, and an escalating demand for non-invasive diagnostic tools. Noteworthy trends expected in the forecast period encompass novel technological advancements, strategic collaborations among biotechnology companies, pharmaceutical entities, and other stakeholders, a surge in research focused on cerebrospinal fluid (CSF) and blood-based biomarkers, and the utilization of AI and machine learning algorithms.

The anticipated increase in neurological illnesses is expected to drive the expansion of the central nervous system biomarker market in the future. Neurological illnesses, also referred to as neurological disorders, encompass a broad spectrum of conditions affecting the brain, spinal cord, and nerves throughout the body. These disorders can result from various factors, including genetic influences, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In the realm of neurological disorders, central nervous system (CNS) biomarkers play a crucial role in clinical diagnosis, determining illness risk or prognosis, assessing disease stage, and monitoring treatment response. They contribute significantly to comprehending these diseases and their treatability. For instance, in April 2023, the Centers for Disease Control and Prevention, a US government agency, reported that Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older, with projections indicating a tripling of this number to 14 million by 2060. Furthermore, the incidence of the disease is observed to double every five years after the age of 65. Consequently, the surge in neurological illnesses is a key factor propelling the growth of the central nervous system biomarker market.

The projected increase in obesity prevalence is poised to drive the growth of the central nervous system biomarker market. Obesity, a medical condition characterized by an excess of body fat that can adversely affect health, is studied using central nervous system biomarkers to comprehend the neurological mechanisms governing body weight, eating behavior, and the development of effective anti-obesity treatments. For example, as of May 2023, the Government Digital Service, a UK-based government body, estimates that 25.9% of individuals (18 years and older) in England are anticipated to be obese in 2021-2022, representing a 25.2% increase. Hence, the escalating prevalence of obesity is a significant driver for the growth of the central nervous system biomarker market.

A prominent trend gaining traction in the central nervous system biomarker market is the approval of innovative drugs. Leading companies in the market are dedicated to developing groundbreaking drugs and obtaining approvals to enhance their market standing. For example, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company based in the US, disclosed the approval and authorization of its investigational new drug (IND) application for DB104 (liafensine) by the US Food and Drug Administration (FDA) for treating treatment-resistant depression (TRD). This marks the initiation of the first biomarker-guided global CNS clinical trial for TRD. The drug has the potential to identify patients more likely to respond to liafensine, facilitating more personalized treatment decisions. Liafensine, a novel compound, functions by elevating levels of dopamine and norepinephrine in the brain.

Major players in the central nervous system biomarker market are strategically focused on introducing advanced solutions, such as assay kits. An assay kit is a pre-packaged set of reagents and materials utilized for a specific scientific analysis. For instance, in June 2023, Sysmex Corporation, a research and development company based in Japan, launched an Automated Immunoassay System. This assay kit is designed to detect amyloid beta (AB) accumulation in the brain, a contributor to Alzheimer's disease, using a small blood sample. The kit measures the ratio of AB peptides in the blood through an automated immunoassay system. This facilitates clinicians in identifying AB accumulation in the brain with a minimal blood sample, enabling earlier diagnosis and treatment for patients.

In June 2022, Fujirebio Holdings Inc., a biotechnology company based in Japan, acquired ADx NeuroSciences for approximately $43 million (40 million euros). This acquisition aims to broaden Fujirebio Holdings' portfolio of central nervous system biomarkers, leverage ADx NeuroSciences' expertise and technology, and enhance its global presence in the central nervous system biomarker market. ADx NeuroSciences, headquartered in Belgium, is a biomarker-assay company specializing in the development and production of biomarkers for central nervous system (CNS) disorders.

Major companies operating in the central nervous system biomarkers market report are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc. , Acumen Pharmaceuticals Inc. , Cassava Sciences Inc., Denali Therapeutics.

North America was the largest region in the central nervous system biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the central nervous system biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The central nervous system biomarkers market consists of sales of diagnostic test kits, assay reagents, antibody drugs, and imaging agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Biomarkers Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Safety Biomarker; Efficacy Biomarker; Validation Biomarker; Other Types
  • 2) By Disease: Multiple Sclerosis; Alzheimer's Disease; Parkinson's Disease; Traumatic Brain Injury; Other Diseases
  • 3) By Application: Drug Discovery And Development; Personalized Medicines; Disease Risk Assessment; Diagnostics; Other Applications
  • 4) By End-Users: Diagnostic Labs; Clinics; Hospitals; Research Centers; Other End-Users
  • Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Siemens Healthineers; Thermo Fisher Scientific Inc; Abbott Laboratories
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Central Nervous System Biomarkers Market Characteristics

3. Central Nervous System Biomarkers Market Trends And Strategies

4. Central Nervous System Biomarkers Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Central Nervous System Biomarkers Market Size and Growth

  • 5.1. Global Central Nervous System Biomarkers Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Central Nervous System Biomarkers Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Central Nervous System Biomarkers Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Central Nervous System Biomarkers Market Segmentation

  • 6.1. Global Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Safety Biomarker
  • Efficacy Biomarker
  • Validation Biomarker
  • Other Types
  • 6.2. Global Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Multiple Sclerosis
  • Alzheimer's Disease
  • Parkinson's Disease
  • Traumatic Brain Injury
  • Other Diseases
  • 6.3. Global Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Drug Discovery And Development
  • Personalized Medicines
  • Disease Risk Assessment
  • Diagnostics
  • Other Applications
  • 6.4. Global Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnostic Labs
  • Clinics
  • Hospitals
  • Research Centers
  • Other End-Users

7. Central Nervous System Biomarkers Market Regional And Country Analysis

  • 7.1. Global Central Nervous System Biomarkers Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Central Nervous System Biomarkers Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Central Nervous System Biomarkers Market

  • 8.1. Asia-Pacific Central Nervous System Biomarkers Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Central Nervous System Biomarkers Market

  • 9.1. China Central Nervous System Biomarkers Market Overview
  • 9.2. China Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Central Nervous System Biomarkers Market

  • 10.1. India Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Central Nervous System Biomarkers Market

  • 11.1. Japan Central Nervous System Biomarkers Market Overview
  • 11.2. Japan Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Central Nervous System Biomarkers Market

  • 12.1. Australia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Central Nervous System Biomarkers Market

  • 13.1. Indonesia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Central Nervous System Biomarkers Market

  • 14.1. South Korea Central Nervous System Biomarkers Market Overview
  • 14.2. South Korea Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Central Nervous System Biomarkers Market

  • 15.1. Western Europe Central Nervous System Biomarkers Market Overview
  • 15.2. Western Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Central Nervous System Biomarkers Market

  • 16.1. UK Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Central Nervous System Biomarkers Market

  • 17.1. Germany Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Central Nervous System Biomarkers Market

  • 18.1. France Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Central Nervous System Biomarkers Market

  • 19.1. Italy Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Central Nervous System Biomarkers Market

  • 20.1. Spain Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Central Nervous System Biomarkers Market

  • 21.1. Eastern Europe Central Nervous System Biomarkers Market Overview
  • 21.2. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Central Nervous System Biomarkers Market

  • 22.1. Russia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Central Nervous System Biomarkers Market

  • 23.1. North America Central Nervous System Biomarkers Market Overview
  • 23.2. North America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Central Nervous System Biomarkers Market

  • 24.1. USA Central Nervous System Biomarkers Market Overview
  • 24.2. USA Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Central Nervous System Biomarkers Market

  • 25.1. Canada Central Nervous System Biomarkers Market Overview
  • 25.2. Canada Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Central Nervous System Biomarkers Market

  • 26.1. South America Central Nervous System Biomarkers Market Overview
  • 26.2. South America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Central Nervous System Biomarkers Market

  • 27.1. Brazil Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Central Nervous System Biomarkers Market

  • 28.1. Middle East Central Nervous System Biomarkers Market Overview
  • 28.2. Middle East Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Central Nervous System Biomarkers Market

  • 29.1. Africa Central Nervous System Biomarkers Market Overview
  • 29.2. Africa Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Central Nervous System Biomarkers Market Competitive Landscape And Company Profiles

  • 30.1. Central Nervous System Biomarkers Market Competitive Landscape
  • 30.2. Central Nervous System Biomarkers Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Novartis AG
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Siemens Healthineers
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Thermo Fisher Scientific Inc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Abbott Laboratories
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Central Nervous System Biomarkers Market Other Major And Innovative Companies

  • 31.1. Merck KGaA
  • 31.2. Eurofins Scientific
  • 31.3. Charles River Laboratories International Inc.
  • 31.4. PerkinElmer Inc.
  • 31.5. Bio-Rad Laboratories Inc.
  • 31.6. QIAGEN N.V.
  • 31.7. Axon Neuroscience SE
  • 31.8. Alector Inc.
  • 31.9. Oryzon Genomics S.A.
  • 31.10. Abastar Mdx Inc.
  • 31.11. Banyan Biomarkers Inc.
  • 31.12. Avacta Group PLC
  • 31.13. Geno Technology Inc.
  • 31.14. Anavex Life Sciences Corp.
  • 31.15. Alseres Pharmaceuticals Inc.

32. Global Central Nervous System Biomarkers Market Competitive Benchmarking

33. Global Central Nervous System Biomarkers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Central Nervous System Biomarkers Market

35. Central Nervous System Biomarkers Market Future Outlook and Potential Analysis

  • 35.1 Central Nervous System Biomarkers Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Central Nervous System Biomarkers Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Central Nervous System Biomarkers Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer